Detalhe da pesquisa
1.
Durable response of lung carcinoma patients to EGFR tyrosine kinase inhibitors is determined by germline polymorphisms in some immune-related genes.
Mol Cancer
; 22(1): 120, 2023 07 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-37516818
2.
Lack of everolimus diffusion in pleural fluid during pleural progression of breast cancer: A case report.
J Oncol Pharm Pract
; 27(1): 235-237, 2021 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-32493163
3.
A decrease in brown adipose tissue activity is associated with weight gain during chemotherapy in early breast cancer patients.
BMC Cancer
; 20(1): 96, 2020 Feb 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-32019525
4.
Correction: Prognostic and predictive role of CD8 and PD-L1 determination in lung tumor tissue of patients under anti-PD-1 therapy.
Br J Cancer
; 121(3): 283, 2019 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-31235866
5.
Iniparib administered weekly or twice-weekly in combination with gemcitabine/carboplatin in patients with metastatic triple-negative breast cancer: a phase II randomized open-label study with pharmacokinetics.
Breast Cancer Res Treat
; 177(2): 383-393, 2019 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-31172407
6.
Prognostic and predictive role of CD8 and PD-L1 determination in lung tumor tissue of patients under anti-PD-1 therapy.
Br J Cancer
; 119(8): 950-960, 2018 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-30318514
7.
Association between lung cancer somatic mutations and occupational exposure in never-smokers.
Eur Respir J
; 50(4)2017 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-29074543
8.
[The anti-tumor immune response in breast cancer: Update and therapeutic perspectives]. / La réponse immunitaire anti-tumorale dans le cancer du sein : état des lieux et perspectives thérapeutiques.
Ann Pathol
; 37(1): 133-141, 2017 Feb.
Artigo
em Francês
| MEDLINE | ID: mdl-28159406
9.
Role of positron emission tomography for the monitoring of response to therapy in breast cancer.
Oncologist
; 20(2): 94-104, 2015 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-25561512
10.
BioCAST/IFCT-1002: epidemiological and molecular features of lung cancer in never-smokers.
Eur Respir J
; 45(5): 1403-14, 2015 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-25657019
11.
Transcriptional expression of 8 genes predicts pathological response to first-line docetaxel + trastuzumab-based neoadjuvant chemotherapy.
BMC Cancer
; 15: 169, 2015 Mar 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-25879949
12.
Use of [(18)F]-FDG PET to predict response to neoadjuvant trastuzumab and docetaxel in patients with HER2-positive breast cancer, and addition of bevacizumab to neoadjuvant trastuzumab and docetaxel in [(18)F]-FDG PET-predicted non-responders (AVATAXHER): an open-label, randomised phase 2 trial.
Lancet Oncol
; 15(13): 1493-1502, 2014 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-25456368
13.
¹8F-FDG PET/CT provides powerful prognostic stratification in the primary staging of large breast cancer when compared with conventional explorations.
Eur J Nucl Med Mol Imaging
; 41(3): 428-37, 2014 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-24196916
14.
HER2-positive breast cancer: ¹8F-FDG PET for early prediction of response to trastuzumab plus taxane-based neoadjuvant chemotherapy.
Eur J Nucl Med Mol Imaging
; 41(8): 1525-33, 2014 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-24647576
15.
Brown adipose tissue activity in relation to weight gain during chemotherapy in breast cancer patients: a pilot study.
Nutr Cancer
; 66(7): 1092-6, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-25157743
16.
Prognostic stratification ability of the CPS+EG scoring system in HER2-low and HER2-zero early breast cancer treated with neoadjuvant chemotherapy.
Eur J Cancer
; 202: 114037, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38554542
17.
Treatment patterns, clinical outcomes and health care costs associated with HER2-positive breast cancer with central nervous system metastases: a French multicentre observational study.
BMC Health Serv Res
; 13: 456, 2013 Oct 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-24176086
18.
Taxane rechallenge during metastatic disease in HER-2 negative breast cancer patients: Clinical activity, tolerance and survival results.
Breast
; 68: 149-156, 2023 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-36773403
19.
Pathologic and immunohistochemical prognostic markers in residual triple-negative breast cancer after neoadjuvant chemotherapy.
Front Oncol
; 13: 1309890, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-38273853
20.
Pathologic complete response and survival in HER2-low and HER2-zero early breast cancer treated with neoadjuvant chemotherapy.
Breast Cancer
; 30(6): 997-1007, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37561255